LEADER 03893oam 2200649 c 450 001 996344224503316 005 20231110222205.0 010 $a3-8394-5185-X 024 7 $a10.14361/9783839451854 035 $a(CKB)4100000011248629 035 $a(DE-B1597)546273 035 $a(OCoLC)1153486440 035 $a(DE-B1597)9783839451854 035 $a(MiAaPQ)EBC6756633 035 $a(Au-PeEL)EBL6756633 035 $a(transcript Verlag)9783839451854 035 $a(MiAaPQ)EBC6956175 035 $a(Au-PeEL)EBL6956175 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54071 035 $a(MiAaPQ)EBC30591554 035 $a(Au-PeEL)EBL30591554 035 $a(EXLCZ)994100000011248629 100 $a20220221d2020 uy 0 101 0 $ager 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aDie multiple Identita?t der Technik$eEine Innovationsbiographie der Augmented Reality-Technologie$fKirstin Lenzen 205 $a1st ed. 210 $aBielefeld$ctranscript Verlag$d2020 215 $a1 online resource (344 p.) 225 0 $aTechnik - Ko?rper - Gesellschaft$v9 311 $a3-8376-5185-1 327 $aFrontmatter 1 Inhalt 5 Geleitwort 9 1. Einleitung 17 2. Vom ?Wesen der Technik? 27 3. Technische Identita?ten als Gegenstand innovationsbiographischer Forschung 61 4. Die narrative Herstellung technischer Identita?ten 125 5. Fallstudie 195 6. Zusammenfassende Betrachtungen 291 Literaturverzeichnis 303 Abbildungs-und Tabellenverzeichnis 339 Danksagung 341 330 $aMenschen haben Identita?ten - Technik auch! Es handelt sich um narrativ hergestellte symbolische Strukturen, die einfache Artefakte sowie Hochtechnologien von der ersten Entwicklungsidee bis zum praktischen Gebrauch begleiten. Sie sind ebenso wandelbar wie vielfa?ltig und sorgen doch fu?r Koha?renz und Kontinuita?t. Unter Ru?ckgriff auf die Biographie- und Lebenslaufforschung entwickelt Kirstin Lenzen erstmalig ein fundiert ausgearbeitetes theoretisches Konzept technischer Identita?t. In ihrer Fallstudie verdeutlicht sie anhand der Augmented Reality-Technologie sowohl die Anwendbarkeit als auch die empirische Relevanz einer innovationsbiographischen Identita?tsrekonstruktion, die u?ber Metaphern hinausgeht. 410 0$aTechnik - Körper - Gesellschaft 606 $aInnovation; Identita?t der Technik; Augmented Reality; Techniksoziologie; Innovationsbiographie; Technik; Wissenschaft; Gesellschaft; Qualitative Sozialforschung; Wissenssoziologie; Soziologie; Identity of Technology; Sociology of Technology; Innovationbiography; Technology; Science; Society; Qualitative Social Research; Sociology of Knowledge; Sociology; 610 $aAugmented Reality. 610 $aInnovationbiography. 610 $aQualitative Social Research. 610 $aScience. 610 $aSociety. 610 $aSociology of Knowledge. 610 $aSociology of Technology. 610 $aSociology. 610 $aTechnology. 615 4$aInnovation; Identita?t der Technik; Augmented Reality; Techniksoziologie; Innovationsbiographie; Technik; Wissenschaft; Gesellschaft; Qualitative Sozialforschung; Wissenssoziologie; Soziologie; Identity of Technology; Sociology of Technology; Innovationbiography; Technology; Science; Society; Qualitative Social Research; Sociology of Knowledge; Sociology; 686 $aMS 4850$qDE-24/20sred$2rvk 700 $aLenzen$b Kirstin$pTechnische Universita?t Berlin, Deutschland$4aut$0909209 712 02$aTechnische Universität Berlin$4fnd$4http://id.loc.gov/vocabulary/relators/fnd 801 0$bDE-B1597 801 1$bDE-B1597 906 $aBOOK 912 $a996344224503316 996 $aDie multiple Identität der Technik$92033739 997 $aUNISA LEADER 11330nam 2200637 a 450 001 9910813685003321 005 20251116170323.0 010 $a1-118-49359-1 010 $a1-299-24140-9 010 $a1-118-49362-1 035 $a(CKB)2560000000098534 035 $a(EBL)1129724 035 $a(SSID)ssj0000831563 035 $a(PQKBManifestationID)12410290 035 $a(PQKBTitleCode)TC0000831563 035 $a(PQKBWorkID)10880837 035 $a(PQKB)10338165 035 $a(MiAaPQ)EBC1129724 035 $a(Au-PeEL)EBL1129724 035 $a(CaPaEBR)ebr10662564 035 $a(CaONFJC)MIL455390 035 $a(OCoLC)829141034 035 $a(BIP)41667866 035 $a(BIP)27776554 035 $a(EXLCZ)992560000000098534 100 $a20121005d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aHuman blood groups /$fGeoff Daniels ; foreword by Ruth Sanger 205 $a3rd ed. 210 $aChichester, West Sussex $cJohn Wiley & Sons$d2013 215 $a1 online resource (544 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a1-4443-3324-0 320 $aIncludes bibliographical references and index. 327 $aCover -- Title page -- Copyright page -- Contents -- Foreword to 1st edition -- Preface to the third edition -- Some abbreviations used -- 1: Human Blood Groups: Introduction -- 1.1 Introduction -- 1.2 Blood group terminology -- 1.2.1 An internationally agreed nomenclature -- 1.2.2 Antigen, phenotype, gene and genotype symbols -- 1.2.3 Blood group systems -- 1.2.4 Collections -- 1.2.5 Low frequency antigens, the 700 series -- 1.2.6 High frequency antigens, the 901 series -- 1.2.7 Blood group terminology used in this book -- 1.3 Chromosomal location of blood group genes -- 1.4 DNA analysis for blood group testing -- 1.4.1 Clinical applications of molecular blood grouping -- 1.4.2 Current and future technologies -- 1.5 Structures and functions of blood group antigens -- 1.5.1 Membrane transporters -- 1.5.2 Receptors and adhesion molecules -- 1.5.3 Complement regulatory glycoproteins -- 1.5.4 Enzymes -- 1.5.5 Structural components -- 1.5.6 Components of the glycocalyx -- 1.5.7 What is the biological significance of blood group polymorphism? -- References -- 2: ABO, H, and Lewis Systems -- Part 1: History and introduction -- Part 2: Biochemistry, inheritance, and biosynthesis of the ABH and Lewis antigens -- 2.2 Structure of ABH, Lewis, and related antigens -- 2.2.1 Glycoconjugates expressing ABH and Lewis antigens -- 2.2.2 Carbohydrate determinants -- 2.3 Biosynthesis, inheritance, and molecular genetics -- 2.3.1 H antigen -- 2.3.2 ABO antigens -- 2.3.3 Lewis antigens -- 2.3.4 Lex, Ley, and sialyl-Lex -- 2.3.5 Other fucosyltransferase genes -- Part 3: ABO, H, and secretor -- 2.4 A1 and A2 -- 2.4.1 A1- and A2-transferases (GTA1 and GTA2) and the genes that produce them -- 2.4.2 A1 and A2 determinants differ quantitatively and qualitatively -- 2.4.3 Aint -- 2.5 ABO phenotype and gene frequencies -- 2.6 Secretion of ABO and H antigens. 327 $a2.6.1 Frequencies -- 2.6.2 Quantitative aspects -- 2.6.3 Sew -- 2.6.4 A, B, and H in plasma -- 2.7 Subgroups of A -- 2.7.1 A3 -- 2.7.2 Aend (Afinn, Abantu) -- 2.7.3 Ax -- 2.7.4 Am -- 2.7.5 Ay -- 2.7.6 Ael -- 2.7.7 Aw -- 2.7.8 Do non-deletional O alleles produce any A antigen? -- 2.8 Subgroups of B -- 2.8.1 B3 -- 2.8.2 Bx -- 2.8.3 Bm -- 2.8.4 Bel -- 2.8.5 Other subgroups of B -- 2.9 Amos and Bmos -- 2.10 A and B gene interaction -- 2.10.1 Allelic competition -- 2.10.2 Allelic enhancement -- 2.11 Overlapping specificities of A- and B-transferases (GTA and GTB) -- 2.11.1 B(A) and A(B) -- 2.11.2 cisAB -- 2.12 H-deficient phenotypes -- 2.12.1 Genetics of red cell H-deficient phenotypes -- 2.12.2 Red cell H-deficient, non-secretor -- the Bombay phenotype -- 2.12.3 Red cell H-partially deficient, non-secretor -- 2.12.4 Red cell H-deficient, secretor -- 2.12.5 Other H-deficient phenotypes -- 2.12.6 I and i expression in H-deficient phenotypes -- 2.13 Acquired alterations of A, B, and H antigens on red cells -- 2.13.1 Acquired B -- 2.13.2 Alterations in leukaemia patients -- 2.13.3 Other acquired changes in ABO antigens -- 2.13.4 In vitro enzymatic degradation of A, B, and H antigens -- 2.13.5 Modification of antigen expression by polyethylene glycol (PEG) -- 2.14 ABH antibodies and lectins -- 2.14.1 Anti-A and -B -- 2.14.2 Anti-A,B of group O serum -- 2.14.3 Clinical significance of ABO antibodies -- 2.14.4 ABO autoantibodies -- 2.14.5 ABO and transplantation -- 2.14.6 Monoclonal antibodies -- 2.14.7 Anti-H -- 2.14.8 Anti-HI and -Hi -- 2.14.9 Lectins -- Part 4: Lewis system -- 2.15 Lea and Leb antigens and phenotypes -- 2.15.1 Red cells -- 2.15.2 Secretions -- 2.15.3 Plasma -- 2.15.4 Uptake of Lewis antigens by red cells -- 2.15.5 Development of Lewis antigens -- 2.15.6 Lewis antigens during pregnancy -- 2.16 Antigen, phenotype, and gene frequencies. 327 $a2.16.1 Red cells -- 2.16.2 Secretions -- 2.17 Lewis antibodies -- 2.17.1 Anti-Lea -- 2.17.2 Anti-Leb -- 2.17.3 Anti-ALeb -- 2.17.4 Clinical significance of Lewis antibodies -- 2.17.5 Lewis antibodies and renal transplantation -- 2.18 Other antigens associated with Lewis -- 2.18.1 Leabx, the antigen originally called Lex -- 2.18.2 Lec and Led -- 2.18.3 Lex, Ley, and sialyl-Lex -- Part 5: Tissue distribution, disease associations, and functional aspects -- 2.19 Expression of ABH and Lewis antigens on other blood cells and in other tissues -- 2.19.1 Leucocytes -- 2.19.2 Platelets -- 2.19.3 Other tissues -- 2.19.4 Tumours -- 2.20 Associations with disease -- 2.20.1 Bacterial infections -- 2.20.2 Viral infections -- 2.20.3 Malaria -- 2.20.4 Clotting -- 2.20.5 Pancreatic cancer -- 2.20.6 Fucosidosis -- 2.21 Functional aspects -- References -- 3: MNS Blood Group System -- 3.1 History and introduction -- 3.2 Biochemistry and molecular genetics -- 3.2.1 Glycophorins -- 3.2.2 Glycophorin A (CD235A) -- 3.2.3 Glycophorin B (CD235B) -- 3.2.4 Cloning and organisation of the genes for GPA, GPB, and GPE -- 3.3 MN and Ss polymorphisms -- 3.3.1 M and N antigens (MNS1 and MNS2) -- 3.3.2 S and s antigens (MNS3 and MNS4) -- 3.3.3 Antigen, gene, and phenotype frequencies -- 3.3.4 Inheritance -- 3.4 Effects of enzyme treatment on the MNSs antigens -- 3.4.1 Proteases -- 3.4.2 Sialidase -- 3.5 The rare glycophorin A-deficient phenotypes En(a?) and MK -- 3.5.1 En(a?) -- 3.5.2 MK -- 3.5.3 Anti-Ena, anti-Wrb, and the determinants they define -- 3.5.4 Pr and Sa antigens and antibodies -- 3.6 U antigen and the GPB-deficient phenotypes S- s- U? and S- s- U+var -- 3.6.1 U (MNS5) and anti-U -- 3.6.2 Biochemistry -- 3.6.3 Molecular genetics -- 3.6.4 Frequency studies -- 3.7 M and N variants representing amino acid substitutions within the N-terminal region of GPA and GPB. 327 $a3.7.1 Mg (MNS11) -- 3.7.2 Mc (MNS8) -- 3.7.3 Fine specificity of MN antibodies -- 3.7.4 He (MNS6) and Me (MNS13) -- 3.8 The Miltenberger series -- 3.9 Hybrid glycophorins and the low frequency antigens associated with them -- 3.10 GP(A-B) variants -- 3.10.1 GP.Hil (Mi.V) and the Hil (MNS20) antigen -- 3.10.2 GP(A-B) hybrids associated with S antigen -- 3.10.3 SAT (MNS36) -- 3.10.4 En(UK) -- 3.11 GP(B-A-B) variants -- 3.11.1 GP.Mur (Mi.III), GP.Hop (Mi.IV), GP.Bun (Mi.VI), and GP.HF (Mi.X) -- 3.11.2 He (MNS6) -- 3.12 GP(A-B-A) variants -- 3.12.1 GP.Dane (Mi.IX) -- DANE (MNS32) and ENDA (MNS44) -- 3.12.2 GP.Vw and GP.Hut -- Vw (MNS9), ENEH (MNS40), and Hut (MNS19) -- 3.12.3 GP.Nob (Mi.VII) and GP.Joh (Mi.VIII) -- Hop (MNS26), Nob (MNS27), and ENKT (MNS29) -- 3.12.4 GP(A-B-A).KI -- 3.12.5 GP(A-B-A).Sat -- 3.13 Further details on Hil, TSEN, MINY, Mur, and Mia -- antigens associated with hybrid glycophorins -- 3.13.1 Hil (MNS20), TSEN (MNS33), and MINY (MNS34) -- 3.13.2 Mur (MNS10) -- 3.13.3 Mia (MNS7) -- 3.14 GP(B-A)-associated variants -- 3.14.1 Dantu (MNS25) -- 3.14.2 Sta (Stones, MNS15) and ERIK (MNS37) -- 3.15 Antigens associated with GPA amino acid substitutions proximal to the membrane and with abnormal expression of Wrb -- 3.15.1 HAG (MNS41) and ENEP (MNS39) -- 3.15.2 MARS (MNS43) and ENAV (MNS42) -- 3.15.3 ENEV (MNS45) -- 3.16 Other low frequency antigens of the MNS system -- 3.16.1 Vr (MNS12) -- 3.16.2 Mta (Martin, MNS14) -- 3.16.3 Ria (Ridley, MNS16) -- 3.16.4 Cla (Caldwell, MNS17) -- 3.16.5 Nya (Nyberg, MNS18) -- 3.16.6 Mv (MNS21) -- 3.16.7 Far (MNS22) -- 3.16.8 sD (Dreyer, MNS23) -- 3.16.9 Mit (Mitchell, MNS24) -- 3.16.10 Or (Orriss, MNS31) -- 3.16.11 Osa (MNS38) -- 3.16.12 MNTD (MNS46) -- 3.17 Antigens associated with atypical glycophorin glycosylation -- 3.17.1 Hu, M1, Tm, Sj, and Can -- 3.17.2 T, Tn, and Cad. 327 $a3.18 M, N, S, s, and U antibodies -- 3.18.1 Human anti-M -- 3.18.2 Human anti-N -- 3.18.3 Clinical significance of anti-M and -N -- 3.18.4 Anti-N and renal dialysis -- 3.18.5 Glucose-dependent antibodies -- 3.18.6 Monoclonal and recombinant anti-M and -N -- 3.18.7 Lectins -- 3.18.8 Anti-S -- 3.18.9 Anti-s -- 3.18.10 Anti-U -- 3.18.11 Anti-UZ and -UX -- 3.19 GYPA mutation assay -- 3.20 Association with Rh -- 3.21 Glycophorins as receptors for pathogens -- 3.21.1 Glycophorins and malaria -- 3.21.2 Other pathogens -- 3.22 Development and distribution of MNS antigens -- 3.23 Function and evolution of glycophorins -- References -- 4: P1PK, Globoside, and FORS Blood Group Systems, plus Some Other Related Blood Groups -- 4.1 Introduction -- 4.2 Biochemistry, biosynthesis, and genetics -- 4.3 P1 (P1PK1) and anti-P1 -- 4.3.1 Frequency and inheritance -- 4.3.2 Variation in strength -- 4.3.3 Development and distribution -- 4.3.4 Other sources of P1 substance -- 4.3.5 Biochemistry and biosynthesis -- 4.3.6 Anti-P1 -- 4.4 Pk phenotype, Pk (P1PK3) antigen, and anti-Pk -- 4.4.1 Pk phenotype -- 4.4.2 Pk antigen, biochemistry, and biosynthesis -- 4.4.3 Pk on other cells -- 4.4.4 Anti-Pk -- 4.5 NOR (PIPK4) antigen and polyagglutination -- 4.6 P (GLOB1) antigen and anti-P -- 4.6.1 P antigen -- 4.6.2 Biochemistry and biosynthesis -- 4.6.3 Anti-P -- 4.7 FORS1 and the Forssman glycolipid -- 4.8 LKE and anti-LKE -- 4.8.1 Frequency and inheritance of LKE -- 4.8.2 Biochemistry and biosynthesis -- 4.8.3 Variation in strength of LKE -- 4.8.4 Development and distribution -- 4.8.5 Involvement of other P antigens -- 4.8.6 Anti-LKE -- 4.9 Sialosylparagloboside and PX2 antigen -- 4.10 p Phenotype and anti-PP1Pk -- 4.10.1 Frequency and inheritance of p phenotype -- 4.10.2 Molecular genetics of p phenotype -- 4.10.3 Biochemical effects of p phenotype. 327 $a4.10.4 Antibodies in serum of p individuals. 330 $aThis new edition of an essential text for all those working within transfusion and blood banking is now even more biologically and clinically relevant, incorporating the latest information on the genes for various blood groups and including greater content on the functional significance of blood groups. 606 $aBlood groups 615 0$aBlood groups. 676 $a612.1/1825 700 $aDaniels$b Geoff$0870782 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910813685003321 996 $aHuman blood groups$92126758 997 $aUNINA